Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LACTULOSE vs DEXTROSE 60% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
Dextrose 60% is a hypertonic solution that increases blood glucose levels, providing a source of calories and fluid. It acts as an osmotic diuretic at high concentrations, drawing water from intracellular to extracellular spaces.
Constipation,Hepatic encephalopathy (portal-systemic encephalopathy)
Intravenous infusion as a caloric source in parenteral nutrition,Treatment of hypoglycemia,Provision of fluid and calories in patients unable to take oral intake
Constipation: 15-30 m L (10-20 g) orally once daily, increased to 45-60 m L (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
250 m L of 60% dextrose (150 g) intravenously over 2 hours for hypoglycemia; for parenteral nutrition, dosage individualized based on caloric requirements and glucose tolerance.
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Approximately 1.5-2.5 hours for exogenous glucose; clinically relevant in monitoring glucose infusion rates in critically ill patients.
Lactulose is not metabolized in the human gastrointestinal tract; it is metabolized by colonic bacteria to lactic acid, acetic acid, and other short-chain fatty acids.
Dextrose is metabolized via glycolysis and the citric acid cycle to produce ATP, carbon dioxide, and water. Insulin facilitates cellular uptake.
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Renal: essentially 100% as CO2 and water; negligible unchanged glucose under normal conditions; in hyperglycemia, small amounts (<5%) excreted unchanged in urine when renal threshold exceeded.
Negligible (<1%). Does not bind significantly to plasma proteins.
Negligible (<5%); glucose is not significantly bound to plasma proteins.
Approximately 0.4 L/kg. Confined to extracellular fluid; minimal tissue distribution due to poor systemic absorption.
Approximately 0.15-0.25 L/kg, approximating extracellular fluid volume; clinically, it indicates distribution primarily in extracellular space.
Oral: <2% due to minimal absorption. Rectal (enema): <2%, essentially no systemic absorption. Systemic bioavailability is negligible.
Intravenous: 100%. Not administered orally for systemic effect; oral glucose is absorbed with near 100% bioavailability but subject to first-pass hepatic metabolism.
No dose adjustment required for renal impairment.
In GFR < 30 m L/min, reduce infusion rate to avoid volume overload and monitor serum glucose; in ESRD, use with caution and consider lower concentration (e.g., 50% dextrose) to minimize fluid load.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of electrolyte disturbances.
In Child-Pugh class C, reduce dose by 30-50% due to impaired gluconeogenesis and risk of hyperglycemia; monitor blood glucose closely.
Infants: 2.5-10 m L/day in divided doses. Children 1-5 years: 5-10 m L/day. Children 6-12 years: 10-15 m L/day. Adolescents: 15-30 m L/day. All doses orally once daily, adjust to produce soft stools.
Neonates: 0.5-1 g/kg/dose (0.8-1.7 m L/kg of 60% dextrose) IV for hypoglycemia; for maintenance, 4-8 mg/kg/min as continuous infusion (adjust concentration to 5-12.5% dextrose). Children: 2 m L/kg of 25% dextrose (0.5 g/kg) IV for hypoglycemia; for parenteral nutrition, start at 5-10 mg/kg/min and titrate.
Initiate at low end of adult dosing (15 m L/day); monitor for electrolyte imbalance and dehydration due to age-related comorbidities and polypharmacy.
Elderly patients: Reduce infusion rate by 20-30% due to decreased glucose tolerance and increased risk of fluid overload; monitor serum glucose and electrolytes frequently.
None
None.
May cause severe diarrhea leading to electrolyte disturbances, hypokalemia, and hypernatremia,Use with caution in patients with galactose intolerance, lactase deficiency, or glucose-galactose malabsorption,Prolonged use may lead to dependence or need for dose escalation,Monitor for symptoms of excessive flatulence and abdominal distension
Risk of hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus or renal impairment,Intravenous administration of hypertonic solutions can cause phlebitis and extravasation injury,Use with caution in patients with intracranial hemorrhage or brain edema due to risk of increasing intracranial pressure
Hypersensitivity to lactulose or any component of the formulation; patients on a galactose-free diet (contains galactose); gastrointestinal obstruction.
Diabetic coma with hyperglycemia,Intracranial hemorrhage (unless used specifically for treatment),Severe dehydration,Known hypersensitivity to dextrose or corn products
No significant food interactions. Lactulose is not absorbed systemically; its action is confined to the colon. However, because it contains galactose and lactose, patients with galactosemia or lactose intolerance should avoid large quantities. Dairy products may exacerbate bloating or gas in some patients. No specific dietary restrictions are required for efficacy.
No direct food interactions; however, dietary intake may need adjustment based on blood glucose levels. Avoid high-sugar foods if hyperglycemia develops. Ensure adequate protein and fat intake to balance parenteral glucose.
Lactulose is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. Based on available data, lactulose is not associated with a significant risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Due to its minimal systemic absorption, the risk of teratogenicity is considered low across all trimesters.
Dextrose 60% is not teratogenic. Hyperglycemia during pregnancy may increase the risk of fetal macrosomia, neonatal hypoglycemia, and congenital anomalies (first trimester). Controlled glucose levels reduce risk.
Lactulose is excreted into breast milk in very small amounts due to its low systemic absorption after oral administration. The M/P (milk-to-plasma) ratio has not been specifically determined, but it is expected to be low. Adverse effects in nursing infants are unlikely. Lactulose is considered compatible with breastfeeding by the American Academy of Pediatrics.
Dextrose is a normal constituent of breast milk. No M/P ratio reported; infusion of 60% dextrose does not pose a risk. Monitor infant for signs of hyperglycemia if maternal infusion is prolonged.
Lactulose pharmacokinetics are not significantly altered during pregnancy. Absorption remains minimal, and no dose adjustment is required. Standard adult dosing (15-30 m L orally, up to 60 m L/day for constipation) is appropriate. Use with caution in patients with risk of fluid/electrolyte imbalance. No dose reduction needed.
Pregnancy increases insulin resistance; dextrose infusion may require higher doses or concurrent insulin to maintain euglycemia. No specific dose change for dextrose itself, but adjust based on glycemic targets.
Lactulose is a non-absorbable disaccharide that acts as an osmotic laxative and also lowers serum ammonia in hepatic encephalopathy by acidifying the colon, trapping ammonium as ammonium ion. In lactulose-dependent patients, diarrhea may indicate overuse or concurrent lactase deficiency; monitor stool frequency. For hepatic encephalopathy, titrate dose to produce 2-3 soft stools per day. Abdominal cramping is common initially; reduce dose temporarily if severe. Long-term use may cause electrolyte disturbances, especially hypokalemia, which can worsen encephalopathy.
Hypertonic dextrose solutions (≥10%) are vesicants; administer via central line to avoid phlebitis and extravasation injury. Monitor serum glucose closely, especially in diabetic or critically ill patients, as rapid infusion can cause hyperglycemia and osmotic diuresis. Use with caution in patients with intracranial hemorrhage or cerebral edema due to risk of hyperosmolarity. Transition to oral or enteral nutrition as soon as feasible to prevent rebound hypoglycemia.
Take lactulose exactly as prescribed; do not increase dose without consulting your doctor.,For constipation, effects may take 24-48 hours; do not use if you have abdominal pain, nausea, or vomiting.,For liver disease, your goal is to have 2-3 soft bowel movements daily; if you have diarrhea, reduce dose; if no bowel movement after 2-3 days, contact your doctor.,Mix lactulose with fruit juice, water, or milk to improve taste; drink plenty of fluids.,May cause gas, bloating, or abdominal cramps, especially early in treatment; these usually improve with continued use.,Do not take other laxatives unless advised by your doctor.,Inform your doctor if you are diabetic (contains galactose and lactose).,Store at room temperature, protect from freezing.
This solution provides sugar (glucose) for energy and fluid replacement.,Tell your healthcare provider if you have diabetes, kidney problems, or any allergies.,Report any pain, redness, or swelling at the infusion site immediately.,Do not eat or drink anything unless instructed by your doctor.,You may need frequent blood sugar checks during therapy.
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LACTULOSE vs DEXTROSE 60% IN PLASTIC CONTAINER, answered by our medical review team.
LACTULOSE is a Laxative that works by Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.. DEXTROSE 60% IN PLASTIC CONTAINER is a Intravenous Hypertonic Dextrose Solution that works by Dextrose 60% is a hypertonic solution that increases blood glucose levels, providing a source of calories and fluid. It acts as an osmotic diuretic at high concentrations, drawing water from intracellular to extracellular spaces.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LACTULOSE and DEXTROSE 60% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LACTULOSE is: Constipation: 15-30 m L (10-20 g) orally once daily, increased to 45-60 m L (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.. The standard adult dose of DEXTROSE 60% IN PLASTIC CONTAINER is: 250 m L of 60% dextrose (150 g) intravenously over 2 hours for hypoglycemia; for parenteral nutrition, dosage individualized based on caloric requirements and glucose tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LACTULOSE and DEXTROSE 60% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LACTULOSE is classified as Category C. Lactulose is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. Based. DEXTROSE 60% IN PLASTIC CONTAINER is classified as Category C. Dextrose 60% is not teratogenic. Hyperglycemia during pregnancy may increase the risk of fetal macrosomia, neonatal hypoglycemia, and congenital anomalies (first trimester). Contro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.